1[1]PatriciaAG, Kandice KM, Emilio DP, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease[J]. Am J Cardiol, 2001, 88:230 - 235
2[2]Mehta SR. Aspirin and clopidogrel in patients with ACS undergoing PCI: CURE and PCI- CURE[J] .J Invasive Cardiol, 2003,15(Suppl B): 17B - 20B
3[3]Simoons ML. Effect of glycoprotein Ⅱ b/Ⅲ a receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV- ACS randomised trial[J].Lancet, 2001, 357(9272): 1915 - 1924
4[4]De Lemos JA, Antman EM, Gibson CM, et al. Abciximab improves both epicardial flow and myocardial reperfusion in ST- elevation myocardial infarction.Observations from the TIMI 14 trial[J]. Circulation,2000, 101(3) :239 - 243
5[5]Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein Ⅱ b/Ⅲa inhibition: the GUSTO V randomised trial[J]. Lancet, 2001, 357(9272) :1905 - 1914
6[6]Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low - molecular- weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT) - 3 PLUS randomized trial in acute myocardial infarction [J ]. Circulation, 2003, 108(2): 135 - 142
7[7]Antman EM, Louwerenburg HW, Baars HF, et al. Enoxaparin as adjunctive antithrombin therapy for STelevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23Trial[J]. Circulation, 2002, 105(14): 1642 - 1649
8[8]Simoons M, Krzeminska - Pakula M, Alonso A, et al.Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI- SK study[J].Eur Heart J, 2002, 23 (16) :1282 - 1290
2Valqimiqli M,Percoco C,Malaqutti P. Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction:a randomized trial[J].JAMA:the Journal of the American Medical Association,2005,(17):2109-2117.
3Niccoli G,Kharbanda RK,Crea F. No-reflow:again prevention is better than treatment[J].EUROPEAN HEART JOURNAL,2010,(20):2449-2455.
